National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Key facts
- Where
- New Delhi, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07131280, who can take part
Where in India
- Institute of Liver & Biliary SciencesNew Delhi, IndiaContact: Dr. Anupam Kumar, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Trial code
- NCT07131280
- Record updated
- 20 August 2025
- Original description
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.Read full original descriptionShow less
National Collaborative Centre for Hepatic Regenerative Medicine(NC-CHRM): To Study the Efficacy of Single vs Repeated Cycle of GCSF+ Darbepoetin in Long Term Transplant Free Management of Patient With Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.
Inclusion: Early decompensated cirrhosis patients with MELD <16.
Exclusion: variceal bleeding in past 3months; Hepatocellular Carcinoma (HCC) or other malignancy; HIV seropositivity; Medically uncontrolled essential hypertension; Viral etiology of liver disease; Co-existent Hepatitis B, Hepatitis C, HIV; Chronic kidney disease; Acute Kidney Injury (AKI) with serum Creatinine >1.5 mg/ dl, multi-organ failure, grade 3 or 4 Hepatic Encephalopathy (HE),; Patients with age less than 18 years or more than 65 years; Patients with Grade III ascites; CHILD C cirrhosis; Patients with a known focus of sepsis; spontaneous Bacterial Peritonitis (SBP); Pregnancy; Lack of informed consent.